Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Aeglea BioTherapeutics, Inc. | Director | Director Stock Option (right to buy) | 43K | Jun 7, 2022 | Direct | ||
Surface Oncology, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 24K | Jun 8, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
SURF | Surface Oncology, Inc. | Jun 8, 2022 | 1 | $0 | 4 | Jun 10, 2022 | Director, 10%+ Owner |
AGLE | Aeglea BioTherapeutics, Inc. | Jun 7, 2022 | 1 | $0 | 4 | Jun 9, 2022 | Director |
AGLE | Aeglea BioTherapeutics, Inc. | Dec 9, 2021 | 3 | $550K | 4 | Dec 13, 2021 | Director |
SURF | Surface Oncology, Inc. | Jun 8, 2021 | 1 | $0 | 4 | Jun 10, 2021 | Director, 10%+ Owner |
AGLE | Aeglea BioTherapeutics, Inc. | Jun 8, 2021 | 1 | $0 | 4 | Jun 9, 2021 | Director |